Aifred Health

What a journey! From a Montreal start-up, to an XPRIZE AI for Good Winner, to Health Canada Approval! Aifred's mission is to solve the treatment choice dilemma for multiple human disease indications, beginning with depression where previously there were no evidence-based methods to choose between almost a dozen approved medications to personalize treatment choice to improve patients outcomes! Congratulations to the Aifred Health founders (David Benrimoh, MD.,CM., MSc., MSc., FRCPC, Robert Fratila, Kelly Perlman, Sonia Israel), our first professional CEO, Marina Massingham, our incredible employees, past and present (but with a special shout-out to our regulatory/clinical director Maud Richard, RAC,  our board of directors (Donald Olds, Steven Abrams, Sandra Stratford MD MSc, Marina Massingham, Ken Atlas, Sarah Bezeau Gervais, François Bergeron), our Montreal ecosystem (District 3 Innovation, Desjardins, MEDTEQ+) and so many, many more that I don't have the space to name and thank! We are now looking for a Canadian commercialization partner and we invite you to contact us if you have an interest in learning more! https://lnkd.in/ezcjx6JN

Quel parcours ! D'une start-up montréalaise à un gagnant du XPRIZE AI for Good, jusqu'à l'approbation de Santé Canada ! La mission d'Aifred est de résoudre le dilemme du choix de traitement pour de multiples indications de maladies humaines, à commencer par la dépression où il n'existait auparavant aucune méthode fondée sur des preuves pour choisir entre près d'une douzaine de médicaments approuvés pour personnaliser le choix de traitement afin d'améliorer les résultats des patients ! Félicitations aux fondateurs d'Aifred Health (David Benrimoh, MD.,CM., MSc., MSc., FRCPC, Robert Fratila, Kelly Perlman, Sonia Israel), à notre première PDG professionnelle, Marina Massingham, à nos incroyables employés, passés et présents (mais avec une mention spéciale pour notre directrice affaires règlementaires/clinique Maud Richard, RAC), à notre conseil d'administration (Donald Olds, Steven Abrams, Sandra Stratford MD MSc, Marina Massingham, Ken Atlas, Sarah Bezeau Gervais, François Bergeron), à notre écosystème montréalais (District 3 Innovation, Desjardins, MEDTEQ+) et à tant d'autres que je n'ai pas l'espace de nommer et de remercier ! Nous recherchons actuellement un partenaire de commercialisation canadien et nous vous invitons à nous contacter si vous souhaitez en savoir plus ! https://lnkd.in/eN52vKcQ

Aifred's Machine Learning Paper published in Nature's Translational Psychiatry! Congratulations to our AI team for this new publication. The importance of our AI technology, developed to provide clinical decision support for medical professionals in disease areas where multiple treatment options exist but where there are no current tools to permit the personalization of treatment choice to drive better patient outcomes, is captured by the first few lines of the article's abstract: "Major depressive disorder (MDD) is the leading cause of disability worldwide, yet treatment selection still proceeds via “trial and error”. Given the varied presentation of MDD and heterogeneity of treatment response, the use of machine learning to understand complex, non-linear relationships in data may be key for treatment personalization." Keep your eye on our page as we look forward to posting more news as we look to publish our clinical trial results and provide you with regulatory updates! Kudos to the authors: Kelly Perlman, Joseph Mehltretter, David Benrimoh, MD.,CM., MSc., MSc., FRCPC Caitrin Armstrong, Robert Fratila, Christina Popescu, Jingla-Fri Tunteng,Colleen Rollins, Grace Golden https://lnkd.in/gdFK5Xmj